Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multiplicity in bone fragility].

Toshitaka Nakamura1

  • 1Department of Orthopaedic Surgery, University of Occupational and Environmental Health.

Clinical Calcium
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis.

Cell·2025
Same author

Lymph node environment drives FSP1 targetability in metastasizing melanoma.

Nature·2025
Same author

Targeting FSP1 triggers ferroptosis in lung cancer.

Nature·2025
Same author

Targeting FSP1 triggers ferroptosis in lung cancer.

bioRxiv : the preprint server for biology·2025
Same author

Interplay of ferroptotic and apoptotic cell death and its modulation by BH3-mimetics.

Cell death and differentiation·2025
Same author

ALDH7A1 protects against ferroptosis by generating membrane NADH and regulating FSP1.

Cell·2025
Same journal

[The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

Clinical calcium·2019
Same journal

[Sequential treatment of osteoporosis with anti-sclerostin.]

Clinical calcium·2019
Same journal

[The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

Clinical calcium·2019
Same journal

[Wnt signaling in myeloma.]

Clinical calcium·2019
Same journal

[Fate decision of hematopoietic stem cells by Wnt signaling.]

Clinical calcium·2019
Same journal

[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

Clinical calcium·2019
See all related articles

Anti-resorptive treatments significantly reduce vertebral fracture risk, with additional benefits from bone mineral density (BMD) increases. Non-vertebral fracture risk also decreases with higher BMD, suggesting improved bone quality.

Area of Science:

  • Bone biology and osteoporosis research.
  • Pharmacological interventions for bone health.
  • Skeletal fragility and fracture prevention.

Context:

  • Osteoporosis poses a significant fracture risk, particularly vertebral and non-vertebral fractures.
  • Anti-resorptive therapies are a cornerstone in managing bone loss.
  • Bone mineral density (BMD) is a key indicator of skeletal health.

Purpose:

  • To quantify the relationship between anti-resorptive treatments, BMD, and fracture risk.
  • To elucidate the mechanisms underlying fracture risk reduction by these therapies.

Summary:

  • Anti-resorptive treatments provide an initial 25% reduction in vertebral fracture risk, with a further 3% decrease for every 1% increase in BMD.
  • Non-vertebral fracture risk shows no initial offset but decreases by 8-27% for every 1% BMD increase.

Related Experiment Videos

  • These effects are attributed to trabecular bone structure stabilization and enhanced bone material strength via secondary mineralization.

    • Impact:

    • Provides quantitative insights into the efficacy of anti-resorptive treatments for different fracture types.
    • Highlights the dual benefit of treatment offset and BMD improvement on fracture risk.
    • Offers a mechanistic explanation for improved bone quality and reduced fragility.